Andrew J. Einhorn
Independent DirectorMr. Andrew J. Einhorn, also known as Andy, CPA., is Financial Advisor of Avista Therapeutics, Inc. He was Chief Financial Officer of Relief Therapeutics Holding SA since May 8, 2024. He serves as Member of Business Advisory Board at Axe Compute Inc. (formerly known as Predictive Oncology Inc.) since June 2023. He is Independent Director of Pelthos Therapeutics Inc. from December 23, 2025. He served as Interim Chief Financial Officer since August 12, 2022 until 2023 & was Principal Financial & Accounting Officer since July 25, 2022 at Cognition Therapeutics, Inc. He served as Chief Financial Officer of Osmotica Holdings Corp Limited (formerly known as Osmotica Pharmaceutical Corp.). since November 9, 2017. Mr. Einhorn served as the Chief Financial Officer at Edge Therapeutics, Inc. from March 2014 to March 10, 2017 and served as its Executive Vice President of Corporate Development in May 2013. Mr. Einhorn served as Chief Financial Officer of Allergan USA, Inc. He served as the Chief Financial Officer of MYOS RENS Technology Inc. (formerly MYOS Corporation) since October 15, 2012 until February 6, 2013. Mr. Einhorn has extensive corporate financial management experience to the role, with experience in investment banking and capital markets, as well as in C-level finance roles at fast-paced clinical and commercial-stage life science companies. Mr. Einhorn serves as a consultant at Danforth Advisors, providing high-level strategic financial guidance to public and private life science companies. He previously worked in capital markets and investment banking for many years. He serves as a venture advisor to the Israel Biotech Fund. He is an employee of Danforth Advisors since July 2022. He is a Corporate finance professional with an extensive background in investment and commercial banking and public accounting. He spent as an investment banker and has extensive experience in corporate finance, capital markets and financial analysis. He was Chief Financial Officer at RVL Pharmaceuticals plc (formerly known as Osmotica Pharmaceuticals plc) since September 2017 until April 18, 2022 and served as its Principal Financial Officer & Principal Accounting Officer until April 18, 2022. Mr. Einhorn has experience in the pharmaceutical industry in the development and execution of corporate strategy. He served as Chief Financial Officer and Executive Vice President of Oceana Therapeutics, Inc from May 2008 to January 2012. He served as Chief Financial Officer and Executive Vice President of Esprit Pharma, Inc. from June 2005 to October 2007. He served as Chief Financial Officer and Executive Vice President of ESP Pharma, Inc. from April 2003 to March 2005, where he was involved in numerous financing, acquisition and licensing transactions across a variety of therapeutic areas and geographies and played a key role in the ultimate sale of those companies to larger pharmaceutical companies. He served as a Managing Director of Credit Lyonnais Securities from June 2001 to May 2003 with responsibilities that included originating and structuring fixed income public transactions, private placements and euro-denominated debt for U.S. issuers. He served as Managing Director of PNC Capital Markets, LLC of Chase Bank USA, N.A. from 1996 to 2001 and Credit Agricole Securities (USA) Inc. He served as Second Vice President of Chase Manhattan Bank (a predecessor company of JPMorgan Chase) from 1983 to 1987. Mr. Einhorn served as Vice President of Chase Bank USA, National Association, a subsidiary of Chase Manhattan Bank from 1989 to 1996. In these positions, he actively engaged in several financial and corporate banking activities, including debt capital markets transactions, private equity financings and international tax-effective financing. He served as Vice President of Bankers Trust Company from 1987 to 1989. He served as Senior Accountant of Touche Ross & Co from 1981 to 1983, where he was responsible for managing audits for healthcare and other industry clients. He is a Certified Public Account and an honor graduate from The American University where he completed a double major in Accounting and Finance.
Positions
- Company NamePelthos Therapeutics Inc.Stock CodePTHSPositionIndependent Director
